Helen M. Thackray - 19 Dec 2024 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role: Chief R&D Officer
Signature: /s/ Alane P. Barnes, by power of attorney
Issuer symbol: BCRX
Transactions as of: 19 Dec 2024
Net transactions value: -$45,049
Form type: 4
Filing time: 23 Dec 2024, 16:15:26 UTC
Previous filing: 17 Dec 2024
Next filing: 02 Apr 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BCRX	Common Stock	Award	$0	+125,950	+48%	$0.000000	390,939	19 Dec 2024	Direct	F1
transaction	BCRX	Common Stock	Tax liability	$45,049	-6,096	-1.6%	$7.39	384,843	19 Dec 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BCRX	Emp. Stock Option (Right to Buy)	Award	$0	+260,950		$0.000000	260,950	19 Dec 2024	Common Stock	260,950	$7.39	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.
F2	Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted Restricted Stock Units. This transaction does not represent a sale by the Reporting Person.
F3	Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.